Tolebrutinib

N/A

Report date: 2026/04/27 20:02:09
NME

Base Information

Drug NameTolebrutinib
Drug Alias NameCenrifkiPRN-2246SAR-442168BTKi('168)BTKi'168
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsRenal InsufficiencyMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[50] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPrincipia Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofiNational Institute Of Neurological Disorders And StrokeGenzyme Corp +[7] 
Inactive CompaniesN/A
Active IndicationsRenal InsufficiencyMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis
Inactive IndicationsMyasthenia Gravis

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG